Clinical trials of All mechanism for melanoma in all type of patients

TrialResults-center www.trialresultscenter.org

1 65279;dacarbazine

Trial	Treatments	Patients	Trials design and methods
65279;dacarbazine monotherapy vs			
Middleton , 2000 n=NA	Dacarbazine 250 mg/m2 on days 15 q 21 days versus Temozolomide 200 mg/m2 on days 15 q 28 days	-	
Falkson , 1998 n=NA	Dacarbazine 200 mg/m2 on days 15 q 28 days versus (a) Dacarbazine 200 mg/m2 on days 15 q 28 days; interferon 15 MU/m2 daily on days 15 then 10 MU/m2 SC 3 times per week q 28 days; tamoxifen 20 mg daily (b) Dacarbazine 200 mg/m2 days 15 q 28 days; tamoxifen 20 mg daily (c) Dacarbazine 200 mg/m2 days 15 q 28 days; interferon 15 MU/m2 daily on days 15 then 10 MU/m2 SC 3/week (repeat every 28 days); tamoxifen 20 mg daily	-	
Luikart , 1984 n=NA	Dacarbazine 250 mg/m2 on days 110 q 28 days versus Vinblastine 6 mg/m2 on days 1& 2, q 28 days; bleomycin 15 units/m2 on days 15 q 28 days; cisplatin 50 mg/m2 on day 5 q 28 days	-	
Kongoniia , 1981 n=NA	Dacarbazine 150 mg/m2 IV days 15 versus Vincristine 1.4 mg/m2 IV days 1, 8, 15; nitrosomethylurea 200 mg/m2 IV days 3, 5, 10, 12; dactinomycin 0.3 mg/m2 IV days 1, 3, 5, 8,10, 12	-	
Moon , 1975 n=NA	(a) Dacarbazine 300 mg/m2 IV daily 6 days q 30 days (b) Dacarbazine 100 mg/m2 IV q8h 6 days q 30 days versus Carmustine 150 mg/m2 IV q 30 days, vincristine 2 mg/m2 IV q 30 days	-	
C. parvum vs			

continued...

Trial	Treatments	Patients	Trials design and methods
Gough , 1978 n=NA follow-up:	Dacarbazine 2.5 mg/kg daily IV 5 days q month versus Dacarbazine 2.5 mg/kg daily IV 5 days q month; C. parvum 7 mg IM 1 week before first dose of dacarbazine and on day 4 q month	-	
epirubicin vs			
Lopez , 1984 n=NA follow-up:	Dacarbazine 250 mg/m2 on days 15 q 21 days versus Dacarbazine 250 mg/m2 on days 15 q 21days; epirubicin 90 mg/m2 on day 1 every 21 days	-	
dacarbazine-vindesine vs Dacarbazine			
Ringborg , 1989 n=NA follow-up:	Dacarbazine 250 mg/m2 days 15 q 28 days versus Dacarbazine 250 mg/m2 days 15 q 28 days; vindesine 3 mg/m2 day 1 q 28 days	-	

References

Middleton, 2000:

Middleton, MR Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000;18:158-66 [10623706] NA

Middleton, MR A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br. J. Cancer 2000;82:1158-62 [10735499] 10.1054/bjoc.1999.1056

Falkson, 1998:

Falkson, CI Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1998;16:1743-51 [9586887] NA

Luikart, 1984:

Kongoniia, 1981:

Moon, 1975:

Moon, JH Comparison of the combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and vincristine with two dose schedules of 5-(3,3-dimethyl-1-triazino) imidazole 4-carboxamide (DTIC) in the treatment of disseminated malignant melanoma. Cancer 1975;35:368-71 [1111913] NA

Gough, 1978:

Gough, IR Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma. Aust N Z J Surg 1978;48:296-300 [281221] NA

Lopez, 1984:

Lopez, M Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest New Drugs 1984;2:319-22 [6392148] NA

Ringborg, 1989:

Ringborg, U Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study. Med Oncol Tumor Pharmacother 1989;6:285-9 [2693850] NA

2 anti-PD-1 antibody

Trial	Treatments	Patients	Trials design and methods
nivolumab vs chemotherapy			
CheckMate 037 (Weber) , 2015 [NCT01721746] n=NA follow-up:	ntravenous infusion of nivolumab 3 mg/kg every 2 weeks until progression or unacceptable toxic eff ects versus investigators choice of chemotherapy (dacarbazine 1000 mg/m every 3 weeks or paclitaxel 175 mg/m combined with carboplatin area under the curve 6 every 3 weeks)	patients with advanced melanoma who progressed after ipilimumab, or ipilimumab and a BRAF inhibitor if they were BRAFV8310;8304;8304; mutation-positive	
pembrolizumab 2mg/kg vs chemotherapy			
KEYNOTE 002 (2mg/kg Q3W) [NCT01704287] n=180/179 follow-up:	Pembrolizumab 2 mg/kg IV Q3W versus Inv. Choice Chemotherapy	patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAFV600 mutation positive, a BRAF inhibitor	Parallel groups open design
nivolumab vs dacarbazine			
CheckMate 066 (Robert) , 2015 [NCT01721772] n=NA follow-up:	nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks versus dacarbazine at a dose of 1000 mg per square meter of body-surface area every 3 weeks	previously untreated patients who had unresectable metastatic melanoma without a BRAF mutation (stage III or IV)	double-blind
nivolumab vs ipilimumab			
CheckMate 238 [NCT02388906] n=NA follow-up:	Nivolumab versus Ipilimumab	patients with Complete Resection of Stage IIIb/c or Stage IV Melanoma	double-blind US
nivolumab + ipilimumab vs ipilimumab			
CheckMate 067 (nivo + ipi) , 2015 [NCT01844505] n=314/315 follow-up:	Nivolumab + ipilumab versus Ipilimumab alone	Previously Untreated Advanced Melanoma	Parallel groups double-blind
pembrolizumab vs ipilimumab			
KEYNOTE-006 (every 2W) , 2015 [NCT01866319] n=279/278 follow-up:	Pembrolizumab Every 2 Weeks or Every 3 Weeks versus Ipilimumab (Participants receive ipilimumab, 3 mg/kg IV, once every 3 weeks for a total oPembrolizumab Every 2 Weeks (Participants receive pembrolizumab, 10 mg intravenously (IV), once every 2 weeks for up to 2 years) 2/ Pembrolizumab Every 3 Weeks (P	patients with unresectable stage III or IV advanced melanoma and who had received no more than one previous systemic therapy for advanced disease	open label

continued...

Trial	Treatments	Patients	Trials design and methods
pembrolizumab vs pembrolizumab			
Hamid , 2013 [NCT01295827] n=NA follow-up:	-	patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not	
pembrolizumab 2mg/kg vs pembrolizumab 10mg/kg			
KEYNOTE-001 , 2014 [NCT01295827] n=89/84 follow-up:	intravenous pembrolizumab at 2 mg/kg every 3 weeks versus intravenous pembrolizumab at 10 mg/kg every 3 weeks	patients (aged 18 years) with advanced melanoma whose disease had progressed after at least two ipilimumab doses	open-label
pembrolizumab vs placebo			
KEYNOTE-054 [NCT02362594] n=NA follow-up:	Pembrolizumab (Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 1 year) versus placebo	patients with complete Resection of High-Risk Stage III Melanoma	double-blind

References

CheckMate 037 (Weber), 2015:

Weber JS, Minor D, DAngelo SP, et al. A phase 3 randomized, open-label studyof nivolumab (anti-PD-1; BMS-936558;ONO-4538) versus investigators choicechemotherapy (ICC) in patients with advancedmelanoma with prior anti-CTLA-4 Presented at the European Society for Medical Oncology 2014 Congress, Madrid, September 2630, 2014. abstract.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackha Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84 [25795410]

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackha Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015 Apr;16:375-84 [25795410] 10.1016/S1470-2045(15)70076-8

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackha Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-84 [25795410]

KEYNOTE 002 (2mg/kg Q3W), :

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sos Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18 [26115796]

CheckMate 066 (Robert), 2015:

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebb C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015 Jan 22;372:320-30 [25399552] 10.1056/NEJMoa1412082

CheckMate 238, 0:

CheckMate 067 (nivo + ipi), 2015:

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015 May 31;: [26027431] 10.1056/NEJMoa1504030

KEYNOTE-006 (every 2W), 2015:

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015 Apr 19;: [25891173] 10.1056/NEJMoa1503093

Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 2017;: [28822576]

Hamid, 2013:

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44 [23724846]

KEYNOTE-001, 2014:

Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-17 [25034862]

10.1016/j.ejca.2015.06.072

KEYNOTE-054, :

3 antiCTLA-4 antibody

Trial	Treatments	Patients	Trials design and methods
ipilimumab 10mg/kg plus dacarbazine vs dacarbazine			
Robert (Ipilimumab) , 2011 [NCT00324155] n=NA follow-up:	ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) versus dacarbazine (850 mg per square meter)	patients with previously untreated metastatic melanoma (stage III (unresectable) or stage IV)	double blind
ipilimumab 3 mg/kg vs gp100			
Hodi , 2010 [NCT00094653] n=NA follow-up:	ipilimumab 3mg/kg every 3 weeks up to 4 treatments versus gp100 alone	patients with previously treated metastatic melanoma patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease	
ipilimumab vs interferon alfa-2b			
Ahmad Tarhini *ongoing* [NCT01274338] n=NA follow-up:	-	-	open label US

continued...

Trial	Treatments	Patients	Trials design and methods
ipilimumab 3 mg/kg vs ipilimumab 10 mg/kg			
CA184-169 *ongoing* [NCT01515189] n=NA follow-up:	Ipilimumab (3 mg/kg) versus Ipilimumab (10 mg/kg)	patients with unresectable or metastatic melanoma	double-blind US
ipilimumab vs placebo			
EORTC Melanoma Group *ongoing* [NCT00636168] n=NA follow-up:	-	patients with complete resection of high risk stage III melanoma	double-blind USA

References

Robert (Ipilimumab), 2011:

Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26 [21639810]

Hodi, 2010:

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb C, Peschel C, Quirt I, Clark JI, Wol Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23 [20525992]

Ahmad Tarhini, 0:

CA184-169, 0:

EORTC Melanoma Group, 0:

Coens C, Suciu S, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb C, Ferraresi V, Smyl Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncol 2017;: [28162999]

4 combined BRAF and MEK inhibition

Trial	Treatments	Patients	Trials design and methods
trametinib and dabrafenib vs dabrafenib			
Long , 2014 [NCT01584648] n=NA follow-up:	dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) versus dabrafenib and placebo	previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation	
Flaherty , 2012 [NCT01072175] n=NA follow-up:	dabrafenib (150 mg) plus trametinib (1 or 2 mg) versus dabrafenib monotherapy	patients with metastatic melanoma and BRAF V600 mutations	

References

Long, 2014:

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandal M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Pro Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-88 [25265492]

Flaherty, 2012:

Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703 [23020132]

5 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.